词条 | Cephalosporin | ||||||||||||||||
释义 |
| Name = Cephalosporin | Image = Cephalosporin core structure.svg | Alt = | Caption = Core structure of the cephalosporins | Use = Bacterial infection | Biological_target = Penicillin binding proteins | ATC_prefix = J01D | MeshID = D002511 | Drugs.com = {{Drugs.com|drug-class|cephalosporins}} | Consumer_Reports = | medicinenet = | rxlist = }} The cephalosporins (sg. {{IPAc-en|ˌ|s|ɛ|f|ə|l|ə|ˈ|s|p|ɔːr|ᵻ|n|,_|ˌ|k|ɛ|-|,_|-|l|oʊ|-}}{{refn|{{MerriamWebsterDictionary|cephalosporin}}}}{{refn|{{cite web |url=https://www.oxforddictionaries.com/definition/english/cephalosporin |title=cephalosporin - definition of cephalosporin in English from the Oxford dictionary |publisher=OxfordDictionaries.com |access-date=2016-01-20 }}}}) are a class of β-lactam antibiotics originally derived from the fungus Acremonium, which was previously known as "Cephalosporium".[1] Together with cephamycins, they constitute a subgroup of β-lactam antibiotics called cephems. Cephalosporins were discovered in 1945, and first sold in 1964.[2] DiscoveryThe aerobic mold which yielded cephalosporin was found in the sea near a sewage outfall in Su Siccu, by Cagliari harbour in Sardinia, by the Italian pharmacologist Giuseppe Brotzu in July 1945.[3] Medical usesCephalosporins are indicated for the prophylaxis and treatment of infections caused by bacteria susceptible to this particular form of antibiotic. First-generation cephalosporins are active predominantly against Gram-positive bacteria, and successive generations have increased activity against Gram-negative bacteria (albeit often with reduced activity against Gram-positive organisms). Adverse effectsCommon adverse drug reactions (ADRs) (≥ 1% of patients) associated with the cephalosporin therapy include: diarrhea, nausea, rash, electrolyte disturbances, and pain and inflammation at injection site. Infrequent ADRs (0.1–1% of patients) include vomiting, headache, dizziness, oral and vaginal candidiasis, pseudomembranous colitis, superinfection, eosinophilia, nephrotoxicity, neutropenia, thrombocytopenia, and fever. The commonly quoted figure of 10% of patients with allergic hypersensitivity to penicillins and/or carbapenems also having cross-reactivity with cephalosporins originated from a 1975 study looking at the original cephalosporins,[4] and subsequent "safety first" policy meant this was widely quoted and assumed to apply to all members of the group.[5] Hence, it was commonly stated that they are contraindicated in patients with a history of severe, immediate allergic reactions (urticaria, anaphylaxis, interstitial nephritis, etc.) to penicillins, carbapenems, or cephalosporins.[6] This, however, should be viewed in the light of recent epidemiological work suggesting, for many second-generation (or later) cephalosporins, the cross-reactivity rate with penicillin is much lower, having no significantly increased risk of reactivity over the first generation based on the studies examined.[5][7] The British National Formulary previously issued blanket warnings of 10% cross-reactivity, but, since the September 2008 edition, suggests, in the absence of suitable alternatives, oral cefixime or cefuroxime and injectable cefotaxime, ceftazidime, and ceftriaxone can be used with caution, but the use of cefaclor, cefadrocil, cefalexin, and cefradine should be avoided.[8] Overall, the research shows that all beta lactams have the intrinsic hazard of very serious hazardous reactions in susceptible patients. Only the frequency of these reactions vary, based on the structure. Recent papers have shown that a major feature in determining frequency of immunological reactions is the similarity of the side chains (e.g., first generation cephalosporins are similar to penicillins), and this is the reason the β-lactams are associated with different frequencies of serious reactions (e.g., anaphylaxis).{{Citation needed|reason=Your explanation here|date=January 2019}} {{See also|Disulfiram-like drug}}Several cephalosporins are associated with hypoprothrombinemia and a disulfiram-like reaction with ethanol.[9][10] These include latamoxef (moxalactam), cefmenoxime, cefoperazone, cefamandole, cefmetazole, and cefotetan. This is thought to be due to the N-methylthiotetrazole side-chain of these cephalosporins, which blocks the enzyme vitamin K epoxide reductase (likely causing hypothrombinemia) and aldehyde dehydrogenase (causing alcohol intolerance).[11] Thus, consumption of alcohol after taking Cephalosporin orally or intravenously is contraindicated, and in severe cases can lead to death.{{Citation needed|reason=Your explanation here|date=January 2019}} Mechanism of actionCephalosporins are bactericidal and have the same mode of action as other β-lactam antibiotics (such as penicillins), but are less susceptible to β-lactamases. Cephalosporins disrupt the synthesis of the peptidoglycan layer forming the bacterial cell wall. The peptidoglycan layer is important for cell wall structural integrity. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by penicillin-binding proteins (PBPs). PBPs bind to the D-Ala-D-Ala at the end of muropeptides (peptidoglycan precursors) to crosslink the peptidoglycan. Beta-lactam antibiotics mimic the D-Ala-D-Ala site, thereby irreversibly inhibiting PBP crosslinking of peptidoglycan. ResistanceResistance to cephalosporin antibiotics can involve either reduced affinity of existing PBP components or the acquisition of a supplementary β-lactam-insensitive PBP. Currently, some Citrobacter freundii, Enterobacter cloacae, Neisseria gonorrhoeae, and Escherichia coli strains are resistant to cephalosporins. Some Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, and Serratia marcescens strains have also developed resistance to cephalosporins to varying degrees.[12] ClassificationThe cephalosporin nucleus can be modified to gain different properties. Cephalosporins are sometimes grouped into "generations" by their antimicrobial properties. The first cephalosporins were designated first-generation cephalosporins, whereas, later, more extended-spectrum cephalosporins were classified as second-generation cephalosporins. Each newer generation has significantly greater Gram-negative antimicrobial properties than the preceding generation, in most cases with decreased activity against Gram-positive organisms. Fourth-generation cephalosporins, however, have true broad-spectrum activity.[13] The classification of cephalosporins into "generations" is commonly practised, although the exact categorization is often imprecise. For example, the fourth generation of cephalosporins is not recognized as such in Japan.{{Citation needed|date=September 2010}} In Japan, cefaclor is classed as a first-generation cephalosporin, though in the United States it is a second-generation one; and cefbuperazone, cefminox, and cefotetan are classed as second-generation cephalosporins. Cefmetazole and cefoxitin are classed as third-generation cephems. Flomoxef and latamoxef are in a new class called oxacephems.[14] Most first-generation cephalosporins were originally spelled "ceph-" in English-speaking countries. This continues to be the preferred spelling in the United States, Australia, and New Zealand, while European countries (including the United Kingdom) have adopted the International Nonproprietary Names, which are always spelled "cef-". Newer first-generation cephalosporins and all cephalosporins of later generations are spelled "cef-", even in the United States.{{citation needed|date=April 2018}} Some state that cephalosporins can be divided into five or even six generations, although the usefulness of this organization system is of limited clinical relevance.[15] Fourth-generation cephalosporins as of March, 2007, were considered to be "a class of highly potent antibiotics that are among medicine's last defenses against several serious human infections" according to the Washington Post.[16] The mnemonic "LAME" is used to note organisms against which cephalosporins do not have activity:{{citation needed|date=April 2018}}
Fifth-generation cephalosporins, however, are effective against MRSA.{{citation needed|date=April 2018}} {{anchor|generations}}
History{{see also|Discovery and development of cephalosporins}}Cephalosporin compounds were first isolated from cultures of Cephalosporium acremonium from a sewer in Sardinia in 1948 by Italian scientist Giuseppe Brotzu.[29] He noticed these cultures produced substances that were effective against Salmonella typhi, the cause of typhoid fever, which had β-lactamase. Guy Newton and Edward Abraham at the Sir William Dunn School of Pathology at the University of Oxford isolated cephalosporin C. The cephalosporin nucleus, 7-aminocephalosporanic acid (7-ACA), was derived from cephalosporin C and proved to be analogous to the penicillin nucleus 6-aminopenicillanic acid (6-APA), but it was not sufficiently potent for clinical use. Modification of the 7-ACA side chains resulted in the development of useful antibiotic agents, and the first agent, cefalotin (cephalothin), was launched by Eli Lilly and Company in 1964. References1. ^{{DorlandsDict|two/000019430|cephalosporin}} 2. ^{{cite book|title=Oxford Handbook of Infectious Diseases and Microbiology|date=2009|publisher=OUP Oxford|isbn=9780191039621|page=56|url=https://books.google.com/books?id=5W-WBQAAQBAJ&pg=PT56}} 3. ^{{cite Q|Q29581637}} 4. ^{{Cite journal|author=Dash CH |title=Penicillin allergy and the cephalosporins |journal=J. Antimicrob. Chemother. |volume=1 |issue=3 Suppl |pages=107–18 |year=1975 |pmid=1201975 |doi=10.1093/jac/1.suppl_3.107}} 5. ^1 {{Cite journal|vauthors=Pegler S, Healy B |title=In patients allergic to penicillin, consider second and third generation cephalosporins for life threatening infections |journal=BMJ |date=10 November 2007 |volume=335 |issue=7627 |pages=991 |pmid= 17991982|doi=10.1136/bmj.39372.829676.47 |pmc=2072043}} 6. ^Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. 7. ^{{Cite journal |author=Pichichero ME |title=Cephalosporins can be prescribed safely for penicillin-allergic patients |journal=The Journal of Family Practice |volume=55 |issue=2 |pages=106–12 |year=2006 |pmid=16451776 |doi= |url=http://www.jfponline.com/pdf%2F5502%2F5502JFP_AppliedEvidence1.pdf |format=PDF |access-date=6 February 2007 |archive-url=https://web.archive.org/web/20120224193547/http://www.jfponline.com/pdf%2F5502%2F5502JFP_AppliedEvidence1.pdf# |archive-date=24 February 2012 |dead-url=yes |df=dmy-all }} 8. ^{{Cite book|title=British National Formulary |publisher=BMJ Publishing Group Ltd and Royal Pharmaceutical Society Publishing |location=London |date=September 2008 |edition=56 |chapter=5.1.2 Cephalosporins and other beta-lactams |pages=295 |isbn=978-0-85369-778-7 |oclc= |doi=}} 9. ^{{Cite journal|author=Kitson TM |title=The effect of cephalosporin antibiotics on alcohol metabolism: a review |journal=Alcohol |volume=4 |issue=3 |pages=143–148 |year=1987 |pmid=3593530|doi=10.1016/0741-8329(87)90035-8}} 10. ^{{Cite journal|author=Shearer MJ |title=Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status |journal=Journal of Clinical Pharmacology |volume=28 |issue=1 |pages=88–95 |year=1988 |pmid=3350995 |doi=10.1002/j.1552-4604.1988.tb03106.x|author2=Bechtold H|author3=Andrassy K|display-authors=3|last4=Koderisch|first4=J|last5=McCarthy|first5=PT|last6=Trenk|first6=D|last7=Jähnchen|first7=E|last8=Ritz|first8=E}} 11. ^{{Cite book|author=Stork CM |veditors=Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA |title=Goldfrank's toxicologic emergencies |chapter=Antibiotics, antifungals, and antivirals |chapterurl=https://books.google.com/books?id=cvJuLqBxGUcC&pg=PA847 |publisher=McGraw-Hill |location=New York |year=2006 |pages=847 |isbn=978-0-07-143763-9 }} 12. ^{{cite web|title=Cephalosporin spectrum of resistance|url=http://antibiotics.toku-e.com/m/?w=cephalosporin|accessdate= 1 July 2012}} 13. ^{{Cite news|url=https://www.merckmanuals.com/professional/infectious-diseases/bacteria-and-antibacterial-drugs/cephalosporins|title=Cephalosporins - Infectious Diseases - Merck Manuals Professional Edition|work=Merck Manuals Professional Edition|access-date=2018-06-14|language=en-US}} 14. ^{{Citation|last=Narisada|first=Masayuki|title=1-Oxacephem Antibiotics|date=1990|last2=Tsuji|first2=Teruji|work=Recent Progress in the Chemical Synthesis of Antibiotics|pages=705–725|publisher=Springer Berlin Heidelberg|language=en|doi=10.1007/978-3-642-75617-7_19|isbn=9783642756191}} 15. ^{{Cite web|url=http://www.hawaii.edu/medicine/pediatrics/pedtext/s06c05.html |title=Case Based Pediatrics Chapter |website= |accessdate=}} 16. ^{{Cite news|url=https://www.washingtonpost.com/wp-dyn/content/article/2007/03/03/AR2007030301311.html|title=FDA Rules override Warnings about Drugs|work=March 4, 2007 |accessdate=|first=Rick|last=Weiss|date=4 March 2007}} 17. ^{{Cite web | last =Jędrzejczyk | first =Tadeusz | title =Internetowa Encyklopedia Leków | website = | publisher =leki.med.pl | date = | url =http://www.leki.med.pl/lek.phtml?id=428&idnlek=2682&menu=4 | doi = | accessdate =2007-03-03 | archive-url =https://web.archive.org/web/20071007165458/http://www.leki.med.pl/lek.phtml?id=428&idnlek=2682&menu=4# | archive-date =7 October 2007 | dead-url =yes | df =dmy-all }} 18. ^The Antimicrobial Drugs, by Eric M. Scholar. Page 108. books.google.com 19. ^{{cite web|url=https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a3.htm?s_cid=mm6131a3_w|title=Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections|website=www.cdc.gov}} 20. ^{{Cite book|author1=Richard L Sweet|author2=Ronald S. Gibbs|title=Infectious Diseases of the Female Genital Tract|url=https://books.google.com/books?id=wuR_ngItU5oC&pg=PA403|accessdate=8 September 2010|date=1 March 2009|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7815-2|pages=403–}} 21. ^{{Cite journal|author=Widmer AF |title=Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus |journal=Clin. Infect. Dis. |volume=46 |issue=5 |pages=656–658 |date=March 2008 |pmid=18225983 |doi=10.1086/526528 }} 22. ^{{Cite journal|vauthors=Kosinski MA, Joseph WS |title=Update on the treatment of diabetic foot infections |journal=Clin Podiatr Med Surg |volume=24 |issue=3 |pages=383–396 |date=July 2007 |pmid=17613382 |doi=10.1016/j.cpm.2007.03.009 |url=http://journals.elsevierhealth.com/retrieve/pii/S0891-8422(07)00026-2}} 23. ^{{Cite journal|author=Kollef MH |title=New antimicrobial agents for methicillin-resistant Staphylococcus aureus |journal=Crit Care Resusc |volume=11 |issue=4 |pages=282–6 |date=December 2009 |pmid=20001879 |doi= |url=}} 24. ^{{Cite journal | pmid = 17145788| pmc = 1803152| year = 2007| author1 = Takeda| first1 = S| title = In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa| journal = Antimicrobial Agents and Chemotherapy| volume = 51| issue = 3| pages = 826–30| last2 = Nakai| first2 = T| last3 = Wakai| first3 = Y| last4 = Ikeda| first4 = F| last5 = Hatano| first5 = K| doi = 10.1128/AAC.00860-06}} 25. ^{{Cite journal | pmid = 18701284| year = 2008| author1 = Toda| first1 = A| title = Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205| journal = Bioorganic & Medicinal Chemistry Letters| volume = 18| issue = 17| pages = 4849–52| last2 = Ohki| first2 = H| last3 = Yamanaka| first3 = T| last4 = Murano| first4 = K| last5 = Okuda| first5 = S| last6 = Kawabata| first6 = K| last7 = Hatano| first7 = K| last8 = Matsuda| first8 = K| last9 = Misumi| first9 = K| last10 = Itoh| first10 = K| last11 = Satoh| first11 = K| last12 = Inoue| first12 = S| doi = 10.1016/j.bmcl.2008.07.085}} 26. ^{{Cite journal | pmid = 21321149| pmc = 3088243| year = 2011| author1 = Sader| first1 = H. S.| title = Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes| journal = Antimicrobial Agents and Chemotherapy| volume = 55| issue = 5| pages = 2390–4| last2 = Rhomberg| first2 = P. R.| last3 = Farrell| first3 = D. J.| last4 = Jones| first4 = R. N.| doi = 10.1128/AAC.01737-10}} 27. ^{{Cite journal | pmid = 23274659| pmc = 3623364| year = 2013| author1 = Craig| first1 = W. A.| title = In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice| journal = Antimicrobial Agents and Chemotherapy| volume = 57| issue = 4| pages = 1577–82| last2 = Andes| first2 = D. R.| doi = 10.1128/AAC.01590-12}} 28. ^{{Cite journal | pmid = 24352909| year = 2014| author1 = Zhanel| first1 = G. G.| title = Ceftolozane/tazobactam: A novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli| journal = Drugs| volume = 74| issue = 1| pages = 31–51| last2 = Chung| first2 = P| last3 = Adam| first3 = H| last4 = Zelenitsky| first4 = S| last5 = Denisuik| first5 = A| last6 = Schweizer| first6 = F| last7 = Lagacé-Wiens| first7 = P. R.| last8 = Rubinstein| first8 = E| last9 = Gin| first9 = A. S.| last10 = Walkty| first10 = A| last11 = Hoban| first11 = D. J.| last12 = Lynch Jp| first12 = 3rd| last13 = Karlowsky| first13 = J. A.| doi = 10.1007/s40265-013-0168-2}} 29. ^Podolsky, M. Lawrence ( ) Cures Out of Chaos: How Unexpected Discoveries Led to Breakthroughs in Medicine and Health, Harwood Academic Publishers External links
3 : Acetaldehyde dehydrogenase inhibitors|Cephalosporin antibiotics|Medical mnemonics |
||||||||||||||||
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。